Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Sanofi, AstraZeneca in respiratory deal

by Rick Mullin
March 13, 2017 | A version of this story appeared in Volume 95, Issue 11

Sanofi Pasteur and MedImmune, the biologics arm of AstraZeneca, have agreed to develop MED18897, a monoclonal antibody, for the prevention of lower respiratory tract illness caused by respiratory syncytial virus. MED18897 is currently in a Phase II clinical trial involving infants ineligible for Synagis, the current standard of care. Sanofi Pasteur will make an up-front payment of $127 million to MedImmune and milestone payments of up to $523 million.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.